施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

盘前交易 03-02 04:22:25 EST

62.37

+1.27

+2.08%

盘前61.82

-0.55-0.88%

04:03 EST

最高62.68	最低61.18	成交量2,074万
今开61.18	昨收61.10	日振幅2.45%
总市值1,270亿	流通市值1,267亿	总股本20.36亿
成交额12.92亿	换手率1.02%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":62.37,"timestamp":1772226000000,"preClose":61.1,"halted":0,"volume":20742639,"hourTrading":{"tag":"盘前","latestPrice":61.82,"preClose":62.37,"latestTime":"04:03 EST","volume":483,"amount":29886.73107,"timestamp":1772442225721,"change":-0.55,"changeRate":-0.008818,"amplitude":0.004008},"delay":0,"changeRate":0.020785597381341996,"floatShares":2031646263,"shares":2035753027,"eps":3.46,"marketStatus":"盘前交易","change":1.27,"latestTime":"03-02 04:22:25 EST","open":61.18,"high":62.675,"low":61.18,"amount":1291579496.466876,"amplitude":0.024468,"askPrice":61.85,"askSize":164,"bidPrice":61.56,"bidSize":100,"shortable":3,"etf":0,"ttmEps":3.46,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772461800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":62.37,"dividendRate":0.039901,"preHourTrading":{"tag":"盘前","latestPrice":61.82,"preClose":62.37,"latestTime":"04:03 EST","volume":483,"amount":29886.73107,"timestamp":1772442225721,"change":-0.55,"changeRate":-0.008818,"amplitude":0.004008},"postHourTrading":{"tag":"盘后","latestPrice":62.25,"preClose":62.37,"latestTime":"19:58 EST","volume":3951282,"amount":246440873.069251,"timestamp":1772240325206,"change":-0.12,"changeRate":-0.001924,"amplitude":0.004008},"volumeRatio":1.7066800068939096,"optionData":{"bulkOrders":[{"symbol":"BMY","call":true,"expireDate":1773979200000,"strike":"62.5","timestamp":1772225677180,"price":1.4,"volume":2500,"amount":350000,"type":"-"},{"symbol":"BMY","call":true,"expireDate":1773979200000,"strike":"62.5","timestamp":1772225837790,"price":1.4,"volume":2498,"amount":349720,"type":"-"}]},"impliedVol":0.2636,"impliedVolPercentile":0.052},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"2613799350","title":"Piper Sandler上调施贵宝目标价至75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613799350","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613799350?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:07","pubTimestamp":1771924028,"startTime":"0","endTime":"0","summary":"Piper Sandler将施贵宝的目标价从66美元上调至75美元，维持“增持”评级。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32023666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"1103835253","title":"施贵宝公布Luspatercept治疗成人α-地中海贫血注册性II期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103835253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103835253?lang=zh_cn&edition=full","pubTime":"2026-02-23 19:59","pubTimestamp":1771847954,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其针对成人α-地中海贫血患者开展的Luspatercept注册性II期临床试验获得积极顶线结果。该研究达到了主要终点，显示Luspatercept在提升血红蛋白水平方面具有显著疗效。安全性数据与既往研究一致，未发现新的安全隐患。\n这一突破性进展为α-地中海贫血患者带来了新的治疗希望。Luspatercept作为首个在该适应症中显示潜力的创新疗法，有望填补当前治疗领域的空白。公司计划与监管机构讨论后续注册路径，加速推动该药物惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2242652126.USD","IE00B2B36J28.USD","LU1032466523.USD","LU1430594728.SGD","LU1868836757.USD","LU1670711123.USD","LU1868836914.USD","IE00BJJMRZ35.SGD","BMY","LU0456855351.SGD","LU0868494617.USD","LU0882574055.USD","BK4581","LU1571399168.USD","LU1093756325.SGD","LU0306807586.USD","LU0985481810.HKD","LU1868837136.USD","LU1883839398.USD","LU2125154778.USD","LU1261432733.SGD","LU1868837300.USD","LU0061475181.USD","LU1718418525.SGD","LU1989771016.USD","LU2242646821.SGD","BK4559","LU1323610961.USD","BK4534","LU1868836591.USD","LU1291159041.SGD","LU1074936037.SGD","IE00BSNM7G36.USD","BK4532","LU0237698245.USD","IE00BFXG1179.USD","BK4585","LU0225284248.USD","LU0225771236.USD","LU1670710661.SGD","LU2360032135.SGD","BK4588","LU0306806265.USD","LU1585245621.USD","BK4007","LU2133065610.SGD","LU1670710588.SGD","LU2125154935.USD","LU0321505868.SGD","LU0321505439.SGD","LU1093756168.USD","LU0114720955.EUR","LU0096364046.USD","LU1670711040.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2612392451","title":"美国FDA受理百时美施贵宝伊伯度胺(Iberdomide)的新药上市申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2612392451","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612392451?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:00","pubTimestamp":1771329628,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0225284248.USD","LU1670711040.USD","LU1261432733.SGD","LU0061475181.USD","LU0456855351.SGD","LU1571399168.USD","LU1989771016.USD","LU2125154778.USD","LU0114720955.EUR","BK4588","LU0321505868.SGD","LU0267386448.USD","LU2242646821.SGD","LU1074936037.SGD","LU1585245621.USD","LU1718418525.SGD","LU1868837136.USD","LU2133065610.SGD","LU1868836591.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU1430594728.SGD","LU1670711123.USD","BK4585","BK4559","LU1670710661.SGD","LU2125154935.USD","LU0306806265.USD","LU1291159041.SGD","BMY","IE00BJT1NW94.SGD","LU0306807586.USD","LU0985481810.HKD","LU0096364046.USD","BK4581","IE00BSNM7G36.USD","LU0868494617.USD","LU0882574055.USD","LU1032466523.USD","LU1670710588.SGD","LU2360032135.SGD","LU0225771236.USD","BK4532","IE0002141913.USD","LU1093756325.SGD","BK4534","IE00BFXG1179.USD","LU1883839398.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"1143149074","title":"美国FDA受理施贵宝针对复发或难治性多发性骨髓瘤患者的新药Iberdomide上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1143149074","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143149074?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:00","pubTimestamp":1771329615,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理施贵宝（Bristol-Myers Squibb）提交的新药Iberdomide上市申请，该药物旨在治疗复发或难治性多发性骨髓瘤患者。这一进展标志着施贵宝在血液肿瘤领域研发的重要里程碑，为患者提供了新的治疗希望。\n多发性骨髓瘤作为一种恶性血液疾病，复发或难治性病例的治疗选择有限，临床需求迫切。Iberdomide作为一种创新疗法，其申请获受理意味着FDA将基于现有数据展开审评，未来可能加速该药物的上市进程。施贵宝持续投入研发，展现了其在肿瘤治疗领域的战略布局与执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU1261432733.SGD","LU1883839398.USD","LU1989771016.USD","LU2125154935.USD","LU0061475181.USD","LU2360032135.SGD","LU0225771236.USD","BK4532","BK4581","LU1868836914.USD","LU1323610961.USD","LU1571399168.USD","LU1670711040.USD","LU1093756168.USD","LU2242646821.SGD","BK4559","LU0882574055.USD","LU1093756325.SGD","LU1868837136.USD","LU0321505439.SGD","IE0009355771.USD","LU0096364046.USD","BK4585","LU0868494617.USD","BK4534","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0237698245.USD","LU0985481810.HKD","LU1670710588.SGD","LU2133065610.SGD","LU0306807586.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0306806265.USD","LU2242652126.USD","LU1291159041.SGD","LU1430594728.SGD","IE0002141913.USD","LU1670711123.USD","LU1868836757.USD","BK4007","LU1032466523.USD","LU1718418525.SGD","LU1074936037.SGD","LU0456855351.SGD","LU1868836591.USD","LU0267386448.USD","IE00B2B36J28.USD","LU1585245621.USD","IE00BFXG1179.USD","LU1670710661.SGD","LU1868837300.USD","LU2125154778.USD","BK4588","IE00BSNM7G36.USD","BMY","LU0321505868.SGD"],"gpt_icon":0},{"id":"2610261682","title":"古根海姆上调施贵宝目标价至72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610261682","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610261682?lang=zh_cn&edition=full","pubTime":"2026-02-09 15:47","pubTimestamp":1770623221,"startTime":"0","endTime":"0","summary":"古根海姆将施贵宝的目标价从62美元上调至72美元，维持“买入”评级。(格隆汇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260209/32007330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"1128483540","title":"异动解读 | 施贵宝盘中大涨5.06%，业绩超预期及乐观展望提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1128483540","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128483540?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:56","pubTimestamp":1770303394,"startTime":"0","endTime":"0","summary":"施贵宝（BMY）今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，公司发布的第四季度业绩超出市场预期，同时给出了高于分析师预测的2026年营收和利润指引，显示出强劲的增长前景。具体而言，其癌症免疫疗法Opdivo销售强劲，血液稀释剂Eliquis的降价策略有望推动收入增长并避免潜在罚款，加之成本削减计划取得进展，共同增强了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMY"],"gpt_icon":0},{"id":"1125300301","title":"施贵宝高管预计：2027年Eliquis销售额将较2026年下滑15亿至20亿美元——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1125300301","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125300301?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:21","pubTimestamp":1770297716,"startTime":"0","endTime":"0","summary":"在最新电话会议中，施贵宝高管透露，公司预计2027年抗凝血药物Eliquis的销售额将较2026年出现显著回落，下降幅度预计在15亿至20亿美元区间。这一预测反映出该明星药物在专利到期后可能面临的市场挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU1323610961.USD","LU1670711123.USD","LU1670711040.USD","LU1868837300.USD","LU1989771016.USD","LU0237698245.USD","IE0002141913.USD","LU1670710661.SGD","LU0114720955.EUR","LU0868494617.USD","LU1718418525.SGD","LU2242646821.SGD","LU1868836591.USD","LU0096364046.USD","LU1291159041.SGD","LU2360032135.SGD","LU1074936037.SGD","LU1571399168.USD","LU1670710588.SGD","LU1868837136.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU0225771236.USD","LU1585245621.USD","LU2125154935.USD","LU2125154778.USD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU0985481810.HKD","LU0061475181.USD","LU0306806265.USD","LU0225284248.USD","LU0321505439.SGD","LU0306807586.USD","IE0009355771.USD","LU1093756325.SGD","LU1093756168.USD","LU0321505868.SGD","BK4007","BK4585","BK4534","LU1261432733.SGD","BK4581","BK4559","LU2242652126.USD","BK4588","LU1430594728.SGD","BK4532","IE00BFXG1179.USD","LU1883839398.USD","LU1868836757.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0267386448.USD","BMY","LU2133065610.SGD","LU0456855351.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2609374724","title":"百时美施贵宝预计2026年营收约460亿至475亿美元 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374724","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609374724?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:02","pubTimestamp":1770292944,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2242646821.SGD","LU0061475181.USD","LU0225284248.USD","LU1670710588.SGD","IE00BJJMRZ35.SGD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU1868836914.USD","LU0237698245.USD","LU1883839398.USD","LU2133065610.SGD","BK4007","LU1032466523.USD","BMY","LU1670710661.SGD","LU0096364046.USD","LU1571399168.USD","BK4559","LU0306807586.USD","BK4581","LU1093756168.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","LU0985481810.HKD","LU0456855351.SGD","LU0225771236.USD","LU1430594728.SGD","LU1868837300.USD","LU1291159041.SGD","IE0002141913.USD","LU1868836757.USD","LU1323610961.USD","LU1585245621.USD","LU2125154935.USD","BK4532","IE00BFXG1179.USD","BK4534","LU1670711040.USD","LU2360032135.SGD","LU0868494617.USD","LU1718418525.SGD","LU0267386448.USD","LU0321505868.SGD","LU1261432733.SGD","LU1670711123.USD","LU2125154778.USD","LU1989771016.USD","LU1093756325.SGD"],"gpt_icon":0},{"id":"1166668975","title":"施贵宝第四季度调整后每股收益受收购IPRD费用及授权收入影响，净额为-0.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166668975","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166668975?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:00","pubTimestamp":1770292803,"startTime":"0","endTime":"0","summary":"施贵宝公司第四季度调整后的每股收益中，计入了因收购相关IPRD（已获产品权益）费用及授权收入所产生的净影响，合计金额为-0.60美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU1261432733.SGD","LU2125154935.USD","LU1585245621.USD","LU0237698245.USD","LU2360032135.SGD","BK4581","LU0114720955.EUR","LU0306807586.USD","LU1670710588.SGD","BK4532","LU1883839398.USD","LU1571399168.USD","BK4534","IE0002141913.USD","IE00BSNM7G36.USD","LU2133065610.SGD","IE00B2B36J28.USD","LU1093756325.SGD","BK4588","BK4559","BMY","LU1868836591.USD","LU0267386448.USD","LU0096364046.USD","LU0456855351.SGD","LU2125154778.USD","IE00BFTCPJ56.SGD","LU0225771236.USD","IE00BFXG1179.USD","LU1670711040.USD","LU0985481810.HKD","LU0868494617.USD","LU1989771016.USD","LU1868837136.USD","LU1032466523.USD","LU1868837300.USD","IE0009355771.USD","LU1670710661.SGD","LU1670711123.USD","IE00BJJMRZ35.SGD","LU1093756168.USD","LU0061475181.USD","BK4007","LU2242652126.USD","LU1291159041.SGD","LU1868836914.USD","LU1074936037.SGD","LU0321505439.SGD","LU0225284248.USD","LU1323610961.USD","LU1718418525.SGD","LU1868836757.USD","LU0306806265.USD","LU1430594728.SGD","LU0321505868.SGD","LU2242646821.SGD","BK4585","LU0882574055.USD"],"gpt_icon":0},{"id":"1126049058","title":"Opdivo®与Yervoy®组合疗法获安大略省快速通道项目纳入报销，成为晚期肝癌一线治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1126049058","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126049058?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:03","pubTimestamp":1770120231,"startTime":"0","endTime":"0","summary":"施贵宝公司研发的免疫疗法组合Opdivo®与Yervoy®近日被加拿大安大略省快速通道医疗项目正式纳入报销范围，作为晚期肝细胞癌患者的一线治疗方案。这一决策使更多患者能够及时获得创新疗法的救治机会。\n该组合疗法通过双重免疫机制激活患者自身免疫系统对抗肿瘤，其临床数据显著优于传统治疗方案。安大略省卫生部门指出，将创新药物纳入快速报销通道体现了医疗体系对晚期癌症患者迫切需求的积极响应。\n此次纳入报销范围的决定预计将惠及省内数百名晚期肝癌患者。医疗专家强调，早期采用有效治疗方案对提升患者生存率和生活质量具有关键意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711123.USD","LU1323610961.USD","BMY","LU2360032135.SGD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU0321505439.SGD","LU1585245621.USD","LU1868836757.USD","LU1430594728.SGD","LU1868837136.USD","LU1670710588.SGD","LU1868836914.USD","LU1868837300.USD","LU0321505868.SGD","LU0061475181.USD","LU0306806265.USD","BK4585","LU1571399168.USD","LU1093756325.SGD","BK4588","LU1261432733.SGD","LU1883839398.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1074936037.SGD","BK4581","BK4007","LU2242652126.USD","LU1291159041.SGD","LU0267386448.USD","IE00B2B36J28.USD","LU0225284248.USD","LU1670710661.SGD","LU1868836591.USD","IE0009355771.USD","IE00BFXG1179.USD","LU1670711040.USD","BK4534","LU1093756168.USD","LU1989771016.USD","BK4532","LU0456855351.SGD","LU0306807586.USD","LU0868494617.USD","LU0096364046.USD","LU0225771236.USD","LU0985481810.HKD","LU1032466523.USD","LU2125154935.USD","LU2133065610.SGD","BK4559","IE00BSNM7G36.USD","LU1718418525.SGD","LU2242646821.SGD","LU0114720955.EUR","LU0237698245.USD","IE00BJT1NW94.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2605149493","title":"生物制药公司Janux Therapeutics与施贵宝达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2605149493","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605149493?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:47","pubTimestamp":1769089661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0306807586.USD","LU2242646821.SGD","LU0061475181.USD","LU0985481810.HKD","IE00BJT1NW94.SGD","LU0096364046.USD","LU0225284248.USD","LU1585245621.USD","LU1989771016.USD","LU0237698245.USD","LU2242652126.USD","IE0009355771.USD","LU1670710588.SGD","LU1430594728.SGD","LU1868836914.USD","IE00BFXG1179.USD","LU1323610961.USD","LU1868837136.USD","LU0321505439.SGD","LU0306806265.USD","LU1571399168.USD","LU0868494617.USD","LU1670711123.USD","LENZ","BK4539","IE0002141913.USD","JANX","IE00B2B36J28.USD","BK4007","IE00BJJMRZ35.SGD","LU0225771236.USD","LU0114720955.EUR","BK4534","LU1074936037.SGD","LU1291159041.SGD","LU0456855351.SGD","LU1261432733.SGD","BK4585","LU1718418525.SGD","BK4559","LU2125154935.USD","LU1868836591.USD","BK4139","LU1093756325.SGD","BK4588","LU1093756168.USD","LU1868837300.USD","IE00BSNM7G36.USD","LU1670710661.SGD","BMY"],"gpt_icon":0},{"id":"2605435278","title":"百时美施贵宝 (BMS) CAR-T疗法启动III期临床，治疗自免疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435278","media":"细胞治疗前沿","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605435278?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:53","pubTimestamp":1768960424,"startTime":"0","endTime":"0","summary":"近日，美国临床试验收录网显示，百时美施贵宝的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验，治疗活动性系统性硬化症。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法，于2020年进入临床阶段。2019年，BMS以740亿美元完成对Celgene的收购，借此将两款关键CAR-T疗法Breyanzi与Abecma纳入其产品管线，正式踏入细胞治疗领域。BMS积极布局，不断强化其在下一代细胞治疗领域的战略纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BSNM7G36.USD","BMS","IE0002141913.USD","CAR","LU0868494617.USD","BK4581","IE00BFXG1179.USD","III","BK4007","LU0225771236.USD","LU0267386448.USD","LU2125154778.USD","LU0306807586.USD","LU0985481810.HKD","LU2360032135.SGD","LU1868836757.USD","LU1291159041.SGD","BK4585","BK4534","LU0096364046.USD","LU0882574055.USD","LU0114720955.EUR","LU0225284248.USD","LU0321505868.SGD","LU2125154935.USD","BMY","IE00BFTCPJ56.SGD","LU1032466523.USD","BK4134","LU1868837136.USD","LU2133065610.SGD","LU1571399168.USD","LU1670711040.USD","BK4532","LU1323610961.USD","IE00BJJMRZ35.SGD","BK4559","LU1868836591.USD","LU0061475181.USD","IE00BJT1NW94.SGD","LU1868836914.USD","LU0306806265.USD","LU1670710661.SGD","LU1670711123.USD","BK4588","LU0321505439.SGD","LU1261432733.SGD","LU1989771016.USD","LU1718418525.SGD","LU2242652126.USD"],"gpt_icon":0},{"id":"2604167611","title":"施贵宝与微软合作利用AI技术加速肺癌的早期检测","url":"https://stock-news.laohu8.com/highlight/detail?id=2604167611","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604167611?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:17","pubTimestamp":1768915060,"startTime":"0","endTime":"0","summary":"格隆汇1月20日｜百时美施贵宝宣布与微软展开合作，旨在通过人工智能技术加速肺癌的早期检测。该合作将通过微软的精准影像网络部署获FDA批准的放射学AI算法，该网络目前被美国超过80%的医院使用。这项技术旨在自动分析X光和CT图像，帮助识别肺部疾病并检测难以发现的肺结节。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120211813a730c84b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120211813a730c84b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4598","IE00BMPRXN33.USD","IE0005OL40V9.USD","LU1697837992.HKD","LU0672654240.SGD","LU2362540622.SGD","IE00B19Z8W00.USD","LU1868837300.USD","BK4554","IE00B19Z9505.USD","IE00BJJMRZ35.SGD","LU0511384066.AUD","LU1988902786.USD","LU1366192091.USD","LU1551013425.SGD","BK4559","LU0094547139.USD","LU1116320737.USD","LU0175139822.USD","LU1181866309.USD","LU2543165471.USD","LU1069347547.HKD","IE00BFSS8Q28.SGD","LU0265550946.USD","LU0354030511.USD","LU1868836757.USD","LU0820561909.HKD","LU0048584097.USD","LU1868836914.USD","LU2242652126.USD","LU2247934214.USD","LU0109392836.USD","LU0345768740.USD","LU0082616367.USD","LU0757359368.USD","SGXZ23171101.USD","BK4527","LU2092627202.USD","LU0342679015.USD","LU0061474705.USD","LU2111349929.HKD","LU1267930813.SGD","LU2430703251.USD","LU0203202063.USD","LU0225283273.USD","LU0306807586.USD","LU0345770308.USD","LU0456855351.SGD","LU1291159041.SGD","LU0690374961.EUR","LU1815333072.USD","LU0823434583.USD","LU0320765059.SGD","LU2592432038.USD","IE0001KFT4U8.USD","LU0171293334.USD","LU0345774391.USD","LU0960925559.SGD","LU0238689110.USD","LU1674673691.USD","LU1935043023.USD","LU0784384876.USD","LU1196500208.SGD","MSFT","LU0889566641.SGD","LU0444973449.USD","LU1633808545.USD","LU0784385840.USD","LU1868837136.USD","LU1035773651.USD","IE00BFTCPJ56.SGD","LU0861579265.USD","LU0096364046.USD","LU0557290698.USD","LU2133065610.SGD","LU1585245621.USD","LU1116320901.HKD","LU1582986433.USD","IE00BSNM7G36.USD","LU2250418816.HKD","IE00BYXW3230.USD","LU1804176565.USD","LU2413666426.HKD","IE00BYQQ9H92.USD","LU1582987324.SGD","LU0310799852.SGD","BK4577","LU1989772923.USD","LU1244550494.USD","LU2106854487.HKD","SG9999014567.USD","LU2125909247.SGD","LU2237443465.HKD","LU1791710582.SGD","LU0323240290.USD","BK4503","LU0426412945.USD","IE00BK4W5M84.HKD","LU0256863811.USD","LU2063271972.USD","SG9999015945.SGD","IE0004091025.USD","LU2347655156.SGD","LU0784385170.HKD","LU0158827781.USD","LU2487616109.SGD","LU2506952170.USD","IE00B19Z8X17.USD","LU1366333091.USD","LU0077335932.USD","LU1623119135.USD","LU0006306889.USD","LU0879622024.SGD","LU0444971666.USD","SG9999004303.SGD","LU0792757196.USD","LU2054465674.USD","LU2505996681.GBP","LU0210528500.USD","LU1059921491.USD","IE0009355771.USD","SG9999015952.SGD","LU2491050071.SGD","SGXZ31699556.SGD","IE00BQXX3D17.EUR","SG9999014898.SGD","LU1720051108.HKD","LU1712237335.SGD","LU0719512351.SGD","LU2430703095.HKD","LU0943347566.SGD","LU0211328371.USD","LU2491050154.USD","LU0965509101.SGD","LU2756315318.SGD","LU2452424414.USD","LU1989773731.SGD","LU1935043536.SGD","LU0011850046.USD","LU1084165304.USD","IE0002141913.USD","LU0267386448.USD","LU0056508442.USD","LU0061474960.USD","LU1435385759.SGD","LU1121112475.USD","LU2413666699.HKD","LU1670711123.USD","LU1582987597.SGD","LU0251132253.USD","LU2023251221.USD","LU2242650005.HKD","SGXZ81514606.USD","LU1003077747.HKD","LU1721428933.USD","IE0034235295.USD","LU2023250843.SGD","IE00B3SWFQ91.USD","IE00BQXX3F31.USD","LU0053666078.USD","LU0316494557.USD","LU0994945656.USD","LU2279689827.SGD","LU1791710400.SGD","LU1548497426.USD","LU0823417653.USD","LU1989771016.USD","SG9999014880.SGD","SG9999015978.USD","LU2095319765.USD","LU1989763005.USD","LU2471134879.HKD","LU2764262908.HKD","IE00B4JS1V06.HKD","LU0314104364.USD","LU2265009873.SGD","LU2506952097.USD","SG9999014542.SGD","LU1043141396.HKD","LU0949170772.SGD","LU2462157665.USD","LU0211327993.USD","BK4587","IE00BMPRXR70.SGD","IE0009356076.USD","LU2298321311.HKD","IE00B1BXHZ80.USD","LU0266013472.USD","SG9999015341.SGD","LU0949170426.SGD","IE00BFSS7M15.SGD","BK4548","LU0689626769.HKD","LU1823568750.SGD","LU1934455863.HKD","LU2347655073.USD","LU0417517546.SGD","LU2108987350.USD","HK0000914686.HKD","LU0128525929.USD","BK4528","LU1670627923.USD","IE00B4YYXB79.USD","LU1815336760.USD","LU0476273544.USD","LU0154236417.USD","LU0823434740.USD","IE000KEQY171.SGD","LU2211815571.USD","LU2357305700.SGD","LU0345769128.USD","IE0004445239.USD","LU0466842654.USD","LU1280957306.USD","LU0187121727.USD","LU2237443895.HKD","LU1670710661.SGD","LU0345770993.USD","IE00BZ1G4Q59.USD","LU2756315664.SGD","LU0757359954.USD","LU1066051811.HKD","LU1235294995.USD","LU1989764664.SGD","LU2361045086.USD","BK4576","SG9999014575.USD","SGXZ99366536.SGD","LU1803068623.USD","BK4550","BK4566","LU0823417737.USD","LU0545562505.USD","LU0127658192.USD","LU2381873111.SGD","LU0234570918.USD","SG9999015986.USD","LU0096362180.USD","IE00BN29S564.USD","SGXZ51526630.SGD","LU1506573853.SGD","IE00BJTD4N35.SGD","LU0965509283.SGD","IE00BDRTCR15.USD","LU0985320562.USD","LU1064131342.USD","LU1323610961.USD","LU0265550359.USD","IE00B775SV38.USD","LU1334329650.SGD","IE0004445015.USD","BK4504","IE00B5949003.HKD","LU2491049909.HKD","LU0203201768.USD","LU0820561818.USD","LU2236285917.USD","LU0210536198.USD","LU1232071149.USD","LU2505996509.AUD","LU0689472784.USD","LU2242646821.SGD","LU2461242641.AUD","LU0097036916.USD","LU2404859667.USD","SG9999017495.SGD","LU1221951129.SGD","LU2275660780.HKD","LU1917777945.USD","LU0210533765.USD","LU0795875169.SGD","LU1093756168.USD","LU0308772762.SGD","LU1839511570.USD","LU2506951958.HKD","LU0321505868.SGD","LU1316542783.SGD","LU1267930490.SGD","LU1934455277.USD","LU0345774631.USD","LU1778281490.HKD","LU1642822529.SGD","LU2237438978.USD","LU2326559502.SGD","LU0061475181.USD","LU2092937148.SGD","LU1935042488.USD","IE00B775H168.HKD","LU0494093205.USD","LU1153585028.USD","LU1228905037.USD","LU0345769631.USD","LU0109391861.USD","LU2433249047.HKD","LU2168563687.JPY","SG9999018865.SGD","LU1145028129.USD","LU0690374615.EUR","LU0965509010.AUD","LU0072462426.USD","LU0889565833.HKD","LU1934455194.USD","LU2471134523.USD","IE0009G5SDU7.USD","LU1066051498.USD","LU1032955483.USD","LU2361044865.SGD","BK4592","LU0256863902.USD","LU1852331112.SGD","LU2210150020.SGD","LU0708994859.HKD","LU2362541273.HKD","LU0528227936.USD","LU1267930730.SGD","BK4535","IE00BHPRN162.USD","LU2264538146.SGD","LU2458330243.SGD","LU0472753341.HKD","BK4538","LU2362541513.USD","LU1037948541.HKD","LU0079474960.USD","LU0353189763.USD","LU1429558221.USD","LU0237698245.USD","IE0034235303.USD","LU1188199696.SGD","LU0289960550.SGD","IE0034235188.USD","LU2168564065.EUR","LU2746668461.USD","LU2458330169.SGD","LU0029864427.USD","LU1496350502.SGD","LU2237443978.SGD","LU0149725797.USD","SG9999002224.SGD","BMY","LU0823421416.USD","LU1732799900.SGD","LU0724617625.USD","LU2148611432.USD","LU1066053197.SGD","HK0000914660.USD","LU2125154778.USD","LU0347712357.USD","LU1989764748.USD","LU2403377893.USD","LU0726765562.USD","LU2360032135.SGD","LU0957791311.USD","LU0795875086.SGD","LU2602419157.SGD","LU1301847155.USD","LU1814569148.SGD","LU2028103732.USD","LU0642271901.SGD","SG9999001077.SGD","LU1074936037.SGD","GB00BDT5M118.USD","IE00B7KXQ091.USD","LU1551013342.USD","LU0640476718.USD","LU0306806265.USD","IE00BN8TJ469.HKD","LU0661504455.SGD","LU0072461881.USD","LU2896262040.SGD","LU0323239441.USD","LU2097829019.USD","LU2552382058.USD","LU2097344357.USD","LU1720051017.SGD","LU2077746001.SGD","IE00BJJMRY28.SGD","LU1066051225.USD","BK4097","LU2023250504.SGD","LU0198837287.USD","LU0683600562.USD","LU2065170008.USD","LU1803068979.SGD","LU2271345857.HKD","LU0868494617.USD","LU2746668974.SGD","BK4516","BK4534","IE00BKVL7J92.USD","LU0882574139.USD","SG9999015358.SGD","LU2065171311.SGD","LU1935042991.SGD","LU2860962120.EUR","LU2764263039.SGD","LU1983260115.SGD","LU2237443622.USD","SG9999001424.SGD","LU1691799644.USD","LU1035775433.USD","LU0321505439.SGD","IE00BFXG1179.USD","LU2471134952.CNY","BK4581","SG9999014914.USD","LU0215105999.USD","LU2041044095.USD","LU2404859741.USD","LU0124676726.USD","LU1732800096.USD","LU0095938881.EUR","LU0738911758.USD","LU1244550577.SGD","LU2244417387.USD","BK4532","LU2430703178.SGD","LU2471134796.USD","LU2552382215.SGD","SG9999018857.SGD","LU2125154935.USD","LU2361044949.HKD","LU0894485498.HKD","BK4579","LU1571399168.USD","IE00BJJMRX11.SGD","LU1267930573.SGD","LU2089283258.USD","LU2168564495.EUR","LU1127390331.HKD","BK4007","LU2360106780.USD","SG9999000418.SGD","LU0057025933.USD","LU2087625088.SGD","LU1235295455.SGD","LU0894486033.HKD","LU1670628061.USD","LU1629891620.HKD","LU0345768153.USD","LU0708995401.HKD","LU1670711040.USD","LU2750360997.AUD","LU0310800379.SGD","LU2242649171.HKD","LU1244550221.USD","IE00BJT1NW94.SGD","LU0276348264.USD","LU1261432733.SGD","BK4543","IE000W1ABFV2.USD","IE00BKPKM429.USD","LU1069344957.HKD","LU1093756325.SGD","LU1868836591.USD","LU0106261372.USD","LU1046421795.USD","IE0003U64NQ7.SGD","LU2065169927.USD","SG9999014906.USD","LU1935042215.USD","LU1228905540.USD","LU0114720955.EUR","IE000YTNTUN2.SGD","LU0823421333.USD","LU1236620750.USD","LU2023250330.USD","LU1564329115.USD","IE00BLSP4239.USD","LU2420271590.USD","LU0302445910.USD","LU2506951875.HKD","LU0390134368.USD","LU0289739343.SGD","LU2237957811.SGD","LU2463028550.USD","LU0081259029.USD","LU0553294199.USD","LU1496350171.SGD","LU2092937221.SGD","SG9999014559.SGD","LU1221951046.USD","LU1236620834.HKD","LU2750360641.GBP","LU1582986359.USD","LU1032466523.USD","BK4533","LU2764263203.CNY","LU0312595415.SGD","IE00B5TLWC47.USD","LU1564329032.USD","LU0225771236.USD","BK4585","LU0225284248.USD","LU2191332357.HKD","LU0787776722.HKD","LU1861127337.USD","LU1119994496.HKD","IE00BQXX3C00.GBP","LU0545039389.USD","LU0289961442.SGD","LU1340139317.AUD","IE00BKDWB100.SGD","LU0234572021.USD","LU0784383803.USD","IE00BDCRKT87.USD","BK4612","LU2237957902.USD","LU1430594728.SGD","SG9999002232.USD","LU0820562030.AUD","LU0069063385.USD","LU0157215616.USD","LU0882574055.USD","LU0314106906.USD","LU0957808578.USD","LU1037948897.HKD","LU2065171402.SGD","LU2083900584.USD","IE000ITXATA3.USD","LU0985481810.HKD","LU0107464264.USD","LU0964807845.USD","LU2213496289.HKD","IE00B1XK9C88.USD","LU0788109477.HKD","LU0426417589.USD","IE00BK4W5L77.USD","LU0158827948.USD","LU0950375773.USD","LU0353189680.USD","GB00B4QBRK32.GBP","LU2552382132.HKD","IE0004086264.USD","LU1043141123.HKD","LU1564329461.SGD","LU2237443549.SGD","LU0348723411.USD","LU0323591593.USD","LU0070217475.USD","LU2210149790.SGD","IE00BJTD4V19.USD","LU2417539215.USD","LU0170899867.USD","LU1989772840.SGD","LU2360108059.USD","LU1974910355.USD","LU0289941410.SGD","LU0965508806.USD","LU1923622614.USD","LU2097344431.USD","IE00BFXG0V08.USD","LU1718418525.SGD","LU1674673428.USD","LU0354030438.USD","LU1564329628.SGD","IE00BWXC8680.SGD","BK4567","LU2286300806.USD","IE00B2B36J28.USD","LU2237443382.USD","BK4525","LU2125909593.SGD","IE00B3S45H60.SGD","IE00BMPRXQ63.HKD","LU0162691827.USD","LU2168564149.EUR","LU1914381329.SGD","LU2456880835.USD","LU0080751232.USD","LU2089284900.SGD","BK4588","IE00BLSP4452.SGD","GB00B4LPDJ14.GBP","IE00BBT3K403.USD","LU2087621335.USD","LU2168564222.USD","LU0912757837.SGD","IE00BJLML261.HKD","LU2720916845.USD","LU1670710588.SGD"],"gpt_icon":0},{"id":"2603253613","title":"百时美施贵宝宣布评估玛伐凯泰治疗青少年有症状的梗阻性肥厚型心肌病（oHCM）的III 期临床试验SCOUT-HCM取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2603253613","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603253613?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:55","pubTimestamp":1768391700,"startTime":"0","endTime":"0","summary":"SCOUT-HCM 的阳性研究结果展现了玛伐凯泰有望成为首个用于青少年 oHCM 患者的心肌肌球蛋白抑制剂。青少年oHCM严重损害健康，主要临床表现与运动耐量下降相关。在欧盟，玛伐凯泰获批用于治疗有症状的NYHA心功能分级II-III级的梗阻性肥厚型心肌病成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4863243_ZH63243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00BJJMRZ35.SGD","LU0985481810.HKD","LU1868837136.USD","LU0306806265.USD","LU1291159041.SGD","LU2242646821.SGD","LU1670710588.SGD","III","IE00BJT1NW94.SGD","LU1989771016.USD","BK4588","LU0456855351.SGD","LU1670710661.SGD","LU0321505439.SGD","LU0868494617.USD","LU0096364046.USD","BK4534","IE00BFXG1179.USD","IE00B2B36J28.USD","LU1323610961.USD","LU1670711123.USD","LU0321505868.SGD","BK4134","BMY","LU1718418525.SGD","LU1571399168.USD","LU0225284248.USD","LU1074936037.SGD","LU0267386448.USD","LU0225771236.USD","LU2242652126.USD","IE0002141913.USD","LU0061475181.USD","LU1868837300.USD","IE00BSNM7G36.USD","IE0009355771.USD","LU1093756168.USD","BK4559","LU0114720955.EUR","BK4585","LU0237698245.USD","LU1868836914.USD","HCM","LU1093756325.SGD","LU1430594728.SGD","LU1585245621.USD","LU1261432733.SGD","LU1868836591.USD","LU2125154935.USD","LU0306807586.USD"],"gpt_icon":0},{"id":"1123126272","title":"施贵宝公布Camzyos（Mavacamten）治疗青少年症状性梗阻性肥厚型心肌病的三期SCOUT-HCM试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123126272","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123126272?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:02","pubTimestamp":1768219344,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其针对青少年症状性梗阻性肥厚型心肌病（oHCM）的药物Camzyos（Mavacamten）所开展的三期SCOUT-HCM临床试验，获得了积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","BK4007","LU0061475181.USD","LU1718418525.SGD","LU2125154935.USD","BMY","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1261432733.SGD","LU1032466523.USD","LU1093756325.SGD","IE00BFXG1179.USD","LU0985481810.HKD","LU1571399168.USD","LU0868494617.USD","BK4534","LU0321505439.SGD","LU2133065610.SGD","LU1989771016.USD","LU0237698245.USD","IE00BJT1NW94.SGD","BK4585","LU0096364046.USD","LU1585245621.USD","BK4581","IE00B2B36J28.USD","LU1868836757.USD","LU0114720955.EUR","LU0306807586.USD","LU0882574055.USD","LU1430594728.SGD","IE00BSNM7G36.USD","IE0002141913.USD","LU2360032135.SGD","LU1868837136.USD","LU2125154778.USD","LU1074936037.SGD","LU1670710661.SGD","IE00BFTCPJ56.SGD","LU0321505868.SGD","LU0306806265.USD","IE0009355771.USD","LU0225771236.USD","LU1093756168.USD","LU1868836914.USD","LU1670710588.SGD","LU1868836591.USD","LU0456855351.SGD","LU2242652126.USD","LU1291159041.SGD","LU1670711123.USD","BK4559","BK4532","BK4588","LU1868837300.USD","LU2242646821.SGD","LU0267386448.USD"],"gpt_icon":0},{"id":"2602379717","title":"不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379717","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602379717?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:50","pubTimestamp":1767966634,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，下周，制药商们将赴旧金山出席摩根大通医疗健康年会，心态较2025年显著放松。多起交易消息公布后，买方股价应声上涨，表明投资者希望它们继续出手。部分交易人士预计，2026年还将好于去年。数据显示，2025年制药商共达成1300亿美元交易，较上年增长124%。在FDA政策走向彻底明朗前，业内普遍预期部分制药商将对重大并购交易采取更为审慎的态度。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391216.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["MRK","BMY","PFE"],"gpt_icon":0},{"id":"2602006340","title":"千亿美元“专利悬崖”逼近！美股制药巨头瞄准收购新药，中小盘生物科技股迎来“超级溢价”投资盛宴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602006340","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602006340?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:00","pubTimestamp":1767945631,"startTime":"0","endTime":"0","summary":"而多种因素共同促成了生物科技并购的爆发式增长。一些全球最畅销的药物正面临在关键地区失去专利保护的风险，这被业内称为“专利悬崖”。据计算，到2032年，畅销品牌专利保护期的丧失将造成至少1739亿美元的年销售额损失。生物科技板块近几年经历繁荣、衰退，然后又是繁荣新冠疫情期间，生物科技行业迅速成为投资者的热门之选。Loren表示，一系列利好数据也推高了生物科技股的估值。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390856.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股制药巨头瞄准收购新药，中小盘生物科技股迎来“超级溢价”投资盛宴？","news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMY","AZN","LLY","NVS","PFE","MRK","NVO","GSK"],"gpt_icon":1},{"id":"2602460753","title":"丰业银行上调施贵宝目标价至60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602460753","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602460753?lang=zh_cn&edition=full","pubTime":"2026-01-09 12:27","pubTimestamp":1767932821,"startTime":"0","endTime":"0","summary":"丰业银行将百时美施贵宝的目标价从53美元上调至60美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260109/31928994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BNS","BMY"],"gpt_icon":0},{"id":"2601542093","title":"瑞银上调施贵宝目标价至65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601542093","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601542093?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:57","pubTimestamp":1767862622,"startTime":"0","endTime":"0","summary":"瑞银将施贵宝的目标价从46美元上调至65美元，评级从“中性”上调至“买入”。(格隆汇)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260108/31926274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"2595406357","title":"高盛上调百时美施贵宝(BMY.US)目标价至57美元，强调其风险回报平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2595406357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595406357?lang=zh_cn&edition=full","pubTime":"2025-12-31 11:49","pubTimestamp":1767152991,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛把百时美施贵宝目标价从 51 美元上调至 57 美元，评级维持“中性”。该行表示，百时美施贵宝在风险与回报之间展现出一种审慎权衡的平衡：股息率 4.6%，派息率约 85%，即便压力增大，仍留有一定空间支撑股息。据了解，百时美施贵宝继续定位为一家全球性生物制药公司，致力于发现、开发和交付创新药物，服务重症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":0.1419},{"period":"3month","weight":0.2677},{"period":"6month","weight":0.322},{"period":"1year","weight":0.0607},{"period":"ytd","weight":0.1563}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.644444,"avgChangeRate":0.008753},{"month":4,"riseRate":0.478261,"avgChangeRate":-0.005913},{"month":5,"riseRate":0.565217,"avgChangeRate":0.002647},{"month":6,"riseRate":0.608696,"avgChangeRate":0.009417},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}